These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 23315386)
21. CT-ultrasound fusion prostate brachytherapy: a dynamic dosimetry feedback and improvement method. A report of 54 consecutive cases. Fuller DB; Jin H; Koziol JA; Feng AC Brachytherapy; 2005; 4(3):207-16. PubMed ID: 16182221 [TBL] [Abstract][Full Text] [Related]
22. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859 [TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460 [TBL] [Abstract][Full Text] [Related]
24. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
25. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience. Martin AG; Roy J; Beaulieu L; Pouliot J; Harel F; Vigneault E Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):334-41. PubMed ID: 17084553 [TBL] [Abstract][Full Text] [Related]
26. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
29. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671 [TBL] [Abstract][Full Text] [Related]
30. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Lee HK; Adams MT; Motta J Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939 [TBL] [Abstract][Full Text] [Related]
31. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning. Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754 [TBL] [Abstract][Full Text] [Related]
32. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related]
33. Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team. Bolla M; Verry C; Giraud JY; Long JA; Conil M; Abidi R; Troccaz J; Colonna M; Descotes JL Cancer Radiother; 2014 Nov; 18(7):643-8. PubMed ID: 25286905 [TBL] [Abstract][Full Text] [Related]
34. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216 [TBL] [Abstract][Full Text] [Related]
36. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953 [TBL] [Abstract][Full Text] [Related]
37. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279 [TBL] [Abstract][Full Text] [Related]
38. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872 [TBL] [Abstract][Full Text] [Related]
39. Impact of race on biochemical disease recurrence after prostate brachytherapy. Yamoah K; Stone N; Stock R Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058 [TBL] [Abstract][Full Text] [Related]
40. The effect of the radial function on I-125 seeds used for permanent prostate implantation. Pickett B; Pouliot J Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]